Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

On November 7, 2011, the U.S. Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized stud...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Cohen, Martin H., Chen, Huanyu, Shord, Stacy, Fuchs, Chana, He, Kun, Zhao, Hong, Sickafuse, Sharon, Keegan, Patricia, Pazdur, Richard
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2013
Teme:
Regulatory Issues: FDA
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639534/
https://ncbi.nlm.nih.gov/pubmed/23576486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0458
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki